Unosi

• Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  C. Hee Suh, A. Berrocal Kasay, E. Chalouhi El-Khouri, P. Miranda, LJ. Božić, S. Jeka, P. Hrycaj, D. Rekalov, P. Wiland, A. Krause, I. Szombati, A. Mihailova, I. Hospodarskyy, M. Piotrowski, S. Ryul Kwon, E. Young Lee, D. Hyun Yoo, W. Park, S. Cheol Shim, S. Joon Lee, T. S. Kwon, Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, American college of rheumatology, pp. 100 - 101, Sep, 2016

• Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  W. Park, LJ. Božić, D. Milakovic, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, P. Shesternya, P. Miranda, F. G. Medina-Rodriguez, P. Wiland, S. Jeka, J. Chavez-Corrales, O. Garmish, T. Linde, D. Rekalov, P. Hrycaj, A. Krause, N. Fomina, O. Piura, M. Abello-Banfi, C. Hee Suh, S. Cheol Shim, S. Joon Lee, S. Young Lee, S. Hwan Kim, D. Hyun Yoo, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, US National Library of Medicine National Institutes of Health, pp. 100 - 101, Sep, 2016

• Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial (2019-06)

  S. Cheol Shim, LJ. Božić, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, F. G Medina-Rodriguez, P. Miranda, P. Shesternya, J. Chavez-Corrales, P. Wiland, S. Jeka, O. Garmish, P. Hrycaj, N. Fomina, W. Park, C. Hee Suh, S. Joon Lee, S. Young Lee, Y. Ju Bae, D. Hyun Yoo, Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial, RHEUMATOLOGY, pp. 2193 - 2202, Jun, 2019

• Spontaneous hybrid crosslinked network induced by multifunctional copolymer towards mechanically-resilient perovskite solar cells (2022-08)

  T. Han, Y. Zhao, J. Yoon, J. Woo, E. Cho, W. Kim, C. Lee, J. Lee, J. Choi, J. Han, J. Nam, K. Wang, S. Priya, M. Balaban, I. Jeon, Y. Yang, Spontaneous hybrid crosslinked network induced by multifunctional copolymer towards mechanically-resilient perovskite solar cells, ADVANCED FUNCTIONAL MATERIALS, No. 2207142, pp. 1 - 12, Aug, 2022

• Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005–2006 (2010-04)

  D. Vulić, S.Lončar, M.Krneta, R.Škrbić, A. Lazarević, Lee BT, Lopez VA, Wong ND, Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005–2006, ARCHIVES OF MEDICAL SCIENCE, No. 2, pp. 183 - 187, Apr, 2010

• Extent of Control of Cardiovasccular Risk Factors and Adcherence to Recommended Therapies in US Multiethnic Adults with Coronary Heart Disease (2010-04)

  D. Vulić, Lee BT, Wong ND, J. Dede, V. A.Lopez, Extent of Control of Cardiovasccular Risk Factors and Adcherence to Recommended Therapies in US Multiethnic Adults with Coronary Heart Disease, AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, Vol. 10, No. 2, pp. 109 - 114, Apr, 2010

• A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study (2013-05)

  D. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanović, M. Abello-Banfi, S. Gutierrez-Ureña, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. Lee, H. Kim, W. Park, U. Müller-Ladner, A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, May, 2013

• FRI0281 The Rate of Positive Conversion in the Quantiferon- TB Gold Test over 2 Years among Patients Treated with CT-P13 or Innovator Infliximab in the Extension Studies of Planetas and Planetra (2014)

  P. Wonung, D. Yoo, P. Hrycaj, N. Prodanović, S. Lee, FRI0281 The Rate of Positive Conversion in the Quantiferon- TB Gold Test over 2 Years among Patients Treated with CT-P13 or Innovator Infliximab in the Extension Studies of Planetas and Planetra, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2014

• FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis (2014)

  D. Yoo, P. Hrycaj, P. Miranda, E. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanović, M. Abello-Banfi, S. Gutierrez-Ureña, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. Lee, H. Kim, W. Park, U. Müller-Ladner, FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2014

• Feasibility of the elliptic flow measurements in pp@LHC using the Lee-Yang zero method (2014-07)

  O. Dordić, J. Milošević, T. Tveter, Feasibility of the elliptic flow measurements in pp@LHC using the Lee-Yang zero method, Physica Scripta, Vol. 89, No. 7, pp. 075301 - 075301, Jul, 2014

• FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud (2016)

  J. Smolen, J. Choe, N. Prodanović, I. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, Z. Lee, Y. Rho, FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016

• Efficacy and safety of CT- P13 (biosimilar infliximab) in patients with rheumatoid arthritis :Comparison betwen switching from reference infliximab to CT-P13 and continuing CT- P13 in the PLANETRA extension study (2016)

  D. Yoo, N. Prodanović, J. Jaworski, P. Miranda, E. Ramiterre, A. Lanzon, A. Baranauskaite, P. Wiland, C. Abud-Mendoza, B. Oparanov, S. Smiyan, H. Kim, S. Lee, S. Kim, W. Park, Efficacy and safety of CT- P13 (biosimilar infliximab) in patients with rheumatoid arthritis :Comparison betwen switching from reference infliximab to CT-P13 and continuing CT- P13 in the PLANETRA extension study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016

• Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results (2017)

  J. Smolen, J. Choe, N. Prodanović, J. Niebrizidovski, I. Staikov, E. Dokoupilova, A. Baranauskaite, R. Iatsishin, M. Mekić, V. Poravska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, I. Lee, I. Rho, Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results, RHEUMATOLOGY, pp. 10 - 10, 2017